Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 versus olmesartan for aortic stiffness in essential hypertension
2012-005720-15Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sacubitril + valsartan and olmesartan in essential hypertension (2 arms), sponsored by Novartis. Primary endpoint: Change in local aortic distensibility. Started Jun 2013; status: completed.
02
Drugs
sacubitril + valsartanolmesartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2012-005720-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005720-15.